Last updated: February 26, 2026
What is the Scope and Content of Patent JP5851691?
Patent JP5851691 pertains to a method for synthesizing specific pharmaceutical compounds, particularly N-arylalkylamides, aimed at improving pharmacokinetics and efficacy. The patent claims cover a novel synthetic route, specific intermediates, and the resulting compounds with potential therapeutic applications, notably as kinase inhibitors.
The patent's primary claims focus on:
- Novel intermediates: Compounds with specific substitution patterns described by chemical formulas.
- Synthetic methods: Processes involving particular reaction conditions and catalysts to produce the compounds.
- Pharmaceuticals: The use of these compounds as active ingredients for treating diseases, especially proliferative disorders like cancer.
The detailed description specifies chemical structures, reaction pathways, and experimental data demonstrating compound efficacy.
How Are the Claims Structured?
Claim Categories
Method Claims: Cover the synthesis process, including:
- Specific starting materials
- Reaction conditions (temperature, solvents, catalysts)
- Sequential steps leading to target compounds
Compound Claims: Define novel chemical entities, including:
- Structural formulas with specific substituents
- Isomers and derivatives explicitly drafted
- Purity levels and stereochemistry considerations
Use Claims: Claim the application of these compounds in medical treatment, notably:
- As kinase inhibitors
- For treating cancer-related diseases
- In formulations demonstrating improved bioavailability
Notable Claim Details
- Claim 1 explicitly covers compounds with a core structure (general formula provided), where various substituents are specified.
- Dependent claims codify specific substitutions and stereochemistry variations.
- Synthetic methods in claims 10-20 specify reaction sequences, catalysts, and purification steps.
- Use claims (e.g., claim 25) claim the therapeutic use of compounds claiming at least 50% inhibition rate in kinase assays.
Landscape and Patent Filing Context
Filing Timeline and Priority Data
- Filing date: August 19, 2014
- Priority date: Shares priority with a PCT application filed in Japan on the same date.
- Grant date: November 22, 2017
Geographic and Patent Family Scope
- Family includes applications in the US (US patent US10264250B2), Europe (EP3188452A1), China, and South Korea.
- The patent family collectively aims to secure global protection for core compounds and processes.
Patent Landscape
| Jurisdiction |
Patent Type |
Publication/Grant Date |
Status |
Key Competitors |
| Japan |
Granted |
Nov 22, 2017 |
Enforced |
Toyama, Takeda, Astellas |
| US |
Granted |
Nov 26, 2019 |
Enforced |
Novartis, Pfizer |
| Europe |
Published |
Feb 7, 2019 |
Pending |
AstraZeneca, Bayer |
| China |
Published |
Aug 6, 2018 |
Pending |
Sinopharm, CSPC |
| South Korea |
Published |
Sep 15, 2018 |
Pending |
Hanmi, Yuhan |
Patent Examiner Art and Litigation
- No public litigation records specific to JP5851691 have been noted.
- Examiner art searches reveal prior art references in patent families and journal literature, primarily from 2005-2012, related to kinase inhibitors and synthetic routes.
Competitive Landscape
- The patent landscape reveals active filings in Japan and international patents by companies like Takeda Pharmaceuticals, Novartis, and AstraZeneca in kinase inhibitor space.
- Similar compounds are claimed in filings across major jurisdictions, indicating competitive innovation in targeted cancer therapies.
Implications for R&D and Commercialization
- The scope of claims suggests potential for broad patent coverage, covering multiple derivatives and synthesis methods.
- The patent’s claims for therapeutic use could support exclusivity for cancer treatments utilizing these compounds.
- Entry barriers exist due to overlapping prior art, but active enforcement in Japan and internationally suggests established rights.
Key Takeaways
- Patent JP5851691 protects specific N-arylalkylamide compounds, their synthesis, and therapeutic methods.
- Claims are categorized into chemical, process, and use, with a focus on kinase inhibitors for cancer.
- The patent family spans multiple jurisdictions, consistent with a strategy for global protection.
- Competition in the kinase inhibitor space remains active, with multiple filings around similar chemical structures and therapeutic targets.
- The scope supports potential license opportunities, especially in Japan and key international markets.
FAQs
1. What key innovations does JP5851691 claim?
It claims novel synthetic pathways and specific structural variations of kinase-inhibiting N-arylalkylamides, with therapeutic applications in cancer.
2. How broad are the patent claims?
The claims cover both specific compounds and methods of synthesis, with multiple dependent claims broadening the scope. Use claims target therapeutic indications.
3. Which jurisdictions does the patent family include?
Japan, US, Europe, China, and South Korea, aiming for broad international protection.
4. Are there similar patents filed by competitors?
Yes, several filings target related kinase inhibitors, indicating high competition with overlapping claims and structures.
5. What are the main patent risks?
Prior art references in kinase inhibitor chemistry could challenge claim validity; ongoing patent examination may lead to claim amendments or rejections.
References:
[1] Patent JP5851691, Official Gazette.
[2] US10264250B2, US Patent.
[3] EP3188452A1, European Patent Application.
[4] International Patent Application WO2014201743, related to kinase inhibitors.
